Gilead Sciences Posts Higher 1Q Sales, Swings to Loss on Charges
By Paul Ziobro
Gilead Sciences posted higher first-quarter sales, but swung to a steep loss due to charges related to recent acquisitions, prompting the company to cut its per-share profit outlook.
The Foster City, Calif.-based biopharmaceutical company reported a loss of $4.17 billion, or $3.34 a share, compared with a profit of $1.01 billion, or 81 cents a share, in the same quarter a year ago.
The latest quarter's results were impacted by a $3.9 billion in-process research and development charge related to its recent $4.3 billion acquisition of CymaBay Therapeutics, as well as a pretax impairment of $2.4 billion related to assets acquired from Immunomedics in 2020.
Adjusted for certain items, Gilead said its per-share loss came to $1.32 a share. Analysts were looking a loss of $1.49 a share, according to FactSet.
Total revenue rose about 5% to $6.67 billion, ahead of analyst expectations for $6.36 billion, primarily due to higher sales of HIV, oncology and liver disease products.
For the full-year, Gilead now expects per-share earnings of between 10 cents and 50 cents, down from its prior view of $5.15 to $5.55. On an adjusted basis, the company expects per-share earnings of $3.45 to $3.85, down from a prior range of $6.85 to $7.25.
It backed its top-line outlook.
Write to Paul Ziobro at paul.ziobro@wsj.com
-0-
Gileadisprovidingfull-year2024guidancebelow:
• Totalproductsalesbetween$27.1billionand$27.5billion.
• Totalproductsales,excludingVeklury,between$25.8billionand$26.2billion.
• TotalVeklurysalesofapproximately$1.3billion.
• DilutedEPSbetween$5.15and$5.55.
• Non-GAAPdilutedEPSbetween$6.85and$7.25.
(END) Dow Jones Newswires
April 25, 2024 16:39 ET (20:39 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back